Although IFNα is effective in treating cervical intraepithelial neoplasia (CIN) and cervical cancer in clinical trials [1, 29], its cytotoxic side effects, which result from high doses of administration, are inevitable. This evidence concerns the gene IFNA17 and cervical squamous intraepithelial neoplasia.